



**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant: **Steven Glazer, et al.**

Application No.: **10/506,954**

Filed: **September 8, 2004**

Entitled: **Interferon Beta-Like Molecules for Treatment of Stroke**

**Maxygen ApS**

, a

**corporation**

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application identified above by virtue of:

[ X ] A chain of title from the inventors, of the patent application identified above, to the current assignee is shown below. The above-identified patent application, USSN 10/506,954, is the US national phase application of International Patent Application No. PCT/DK03/00127, which was filed on February 28, 2003. Maxygen ApS is the assignee of the entire right, title, and interest of the above-identified patent application USSN 10/506,9954 as shown by the chain of title below:

1. An assignment of priority Danish Patent Application No. PA 2002 00371, filed March 12, 2002, from inventor Steven Glazer to Maxygen ApS. A copy of this assignment is attached.
  2. An assignment of International Patent Application No. PCT/DK03/00127, filed February 28, 2003, from inventor Steven Glazer to Maxygen ApS. A copy of this assignment is attached.
  3. An assignment of priority Danish Patent Application No. PA 2002 00371, filed March 12, 2002, from inventor Thomas Sager to H. Lundbeck A/S. A copy of this assignment is attached.
  4. An assignment of International Patent Application No. PCT/DK03/00127, filed February 28, 2003, from inventor Thomas Sager to H. Lundbeck A/S. A copy of this assignment is attached.
  5. An assignment of International Patent Application No. PCT/DK03/00127, filed February 28, 2003, from assignee H. Lundbeck A/S to Maxygen ApS. A copy of this assignment is attached.
- [X] Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

June 8, 2005

Date

Signature

**Michael S. Rabson**

Typed or printed name

**Sr. Vice President and General  
Counsel**

Title

# ASSIGNMENT

I, the undersigned,

GLAZER, Steven  
Tagensvej 36, 5 th  
DK-2200 Copenhagen N.  
Denmark

# COPY

(hereinafter referred to as the Assignors) hereby confirms that in consideration of the sum of one dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we have assigned all our right, title and interest in and to the invention entitled

## NEW USE OF INTERFERON BETA

for which a Danish patent application was filed on 12 March 2002 under number PA 2002 00371 to:

Maxygen ApS  
Agern Allé 1  
DK-2970 Hørsholm  
Denmark

a company existing under the laws of Denmark (hereinafter referred to as the Assignee/Assignees).

This assignment covers all countries of the world and the Assignee/Assignees is/are hereby entitled to file applications in any country at its/their discretion and to abstain from seeking patent protection in any and all countries, if it/they so desires/desire.

This Assignment also includes my/our right to claim priority under the Paris Convention or any other multilateral or bilateral treaties.

The Assignor/Assignors hereby agree to execute any additional assignments and other documents required in connection with the prosecution of the patent applications as well as to perform any additional acts necessary to enable the Assignee/Assignees or its/their successors, legal representatives and assigns, to enjoy the full rights of this assignment, including applying for a patent for the invention in the United States of America, and assigning the U.S. patent application and any patent or patents issuing thereon to the said Assignee/Assignees or its/their successors, legal representatives and assigns.

Place and date:

*Hørsholm, June 6, 2002*

Assignor:

*Steven Glazer*  
Steven Glazer

Place and date

*Hørsholm, 06-JUN-2002*

Witness:

*Dorthe Jørgensen*  
Dorthe Jørgensen  
Eskemosegårds Allé 4  
DK-3460 Birkerød

Place and date:

*Hørsholm 6/6-02*

Assignee:

Maxygen ApS

*Kim Wagner*  
Kim Wagner

Place and date

*Hørsholm, 06-JUN-2002*

Witness:

*Dorthe Jørgensen*  
Dorthe Jørgensen  
Eskemosegårds Allé 4  
DK-3460 Birkerød

# ASSIGNMENT

# COPY

I, the undersigned,

GLAZER, Steven  
Tagensvej 36, 5 th  
DK-2200 Copenhagen N..  
Denmark

(hereinafter referred to as the Assignors) hereby confirms that in consideration of the sum of one dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I have assigned all my right, title and interest in and to the invention entitled

INTERFERON BETA-LIKE MOLECULES FOR TREATMENT OF STROKE

for which a PCT patent application was filed on 28 February 2003 under number PCT/DK03/00127 to:

Maxygen ApS  
Agern Allé 1  
DK-2970 Hørsholm  
Denmark

a company existing under the laws of Denmark (hereinafter referred to as the Assignee/Assignees).

This assignment covers all countries of the world and the Assignee/Assignees is/are hereby entitled to file applications in any country at its/their discretion and to abstain from seeking patent protection in any and all countries, if it/they so desires/desire.

This Assignment also includes my/our right to claim priority under the Paris Convention or any other multilateral or bilateral treaties.

The Assignor/Assignors hereby agree to execute any additional assignments and other documents required in connection with the prosecution of the patent applications as well as to perform any additional acts necessary to enable the Assignee/Assignees or its/their successors, legal representatives and assigns, to enjoy the full rights of this assignment, including applying for a patent for the invention in the United States of America, and assigning the U.S. patent application and any patent or patents issuing thereon to the said Assignee/Assignees or its/their successors, legal representatives and assigns.

Place and date:

*Hørsholm, 24/04/03*

Assignor:

*Steven Glazer*  
\_\_\_\_\_  
Steven Glazer

Place and date

*Hørsholm, 24/04/03*

Witness:

*Dorthe Jørgensen*  
\_\_\_\_\_  
Dorthe Jørgensen  
Eskemosegårds Allé 4  
DK-3460 Birkerød

Place and date:

*Hørsholm, 24/04/03*

Assignee:

Maxygen ApS

*Kim Wagner*  
\_\_\_\_\_  
Kim Wagner

Place and date

*Hørsholm, 24/04/03*

Witness:

*Dorthe Jørgensen*  
\_\_\_\_\_  
Dorthe Jørgensen  
Eskemosegårds Allé 4  
DK-3460 Birkerød

# ASSIGNMENT

406 DK

I,

Thomas Sager  
Stormosevej 35  
DK-2765 Smørum  
Denmark

**COPY**

as the inventor, do hereby agree to assign, and hereby do assign, transfer and set over to

H. LUNDBECK A/S  
9, Ottiliavej  
DK-2500 COPENHAGEN-Valby  
DENMARK

(hereinafter designated the assignee), its successors, assignees and legal representatives, the entire right, title and interest in and to all subject matter invented by me and disclosed in Danish Patent Application No. PA 2002 00371 filed on 12 March 2002 and corresponding patent applications, entitled

"Interferon Beta-like molecules for treatment of stroke"

and in and to any and all divisional applications thereof; and in and to all corresponding patent applications and all Convention and Treaty Rights of any kind in all countries throughout the world, for all such subject matter.

Further, I agree that I will communicate to said assignee or its representatives, any facts known to me respecting said invention, and testify in any legal proceedings, sign all lawful papers, execute all necessary assignment papers to cause any and all patents on said invention to be issued to said assignee, make all rightful oaths and generally do everything necessary or desirable to aid said assignee, its successors and assignees, to obtain and enforce proper protection for said invention.

The assignment does not involve payment of a consideration exceeding DKK 10 000.

Valby 2/6-03  
Place & Date

  
\_\_\_\_\_  
Thomas Sager, inventor

## ASSIGNMENT OF PATENT APPLICATION

WHEREAS, Thomas Sager of 35 Stormosevej, DK-2765 Smørum, Denmark, hereinafter referred to as "Assignor," is an inventor of the invention described and set forth in the below-identified international application:

Title of Invention: Interferon Beta-Like Molecules for Treatment of Stroke

Filing Date: 28 February 2003

Application No.: PCT/DK03/00127; and


WHEREAS, H. Lundbeck A/S, of 9, Ottiliavej, DK-2500 Valby, Denmark, hereinafter referred to as "Assignee," is desirous of acquiring an interest in the invention and application and in any Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by these presents does assign to Assignee all right, title and interest in and to the invention and application and to all national phase and foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in all countries throughout the world, and which claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignor further agrees that Assignor will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of the above-identified international patent application and any national phase and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee or Assignee's successors and assigns.


IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: 26 July 2004  
Place: Valby

  
Assignor Thomas Sager

SIGNATURE WITNESSED BY:


Date: 26 July 2004  
Place: Valby

  
Signature of Witness

VIBEKE MØLLER NIELSEN  
Printed Name of Witness


ASSIGNEE:

Date: 26 July 2004  
Place: Valby

  
Assignee H. Lundbeck (please sign and print name/title of representative)  
LARS BOKSERUMGAARD, SECTION LEADER,  
CORPORATE PATENTS

SIGNATURE WITNESSED BY:

Date: 26 July 2004  
Place: Valby

  
Signature of Witness

VIBEKE MØLLER NIELSEN  
Printed Name of Witness

**COPY**

# ASSIGNMENT OF PATENT APPLICATION

WHEREAS, H. Lundbeck A/S, of 9, Ottiliavej, DK-2500 Valby, Denmark, hereinafter referred to as "Assignor," is an owner and co-applicant of the below-identified international patent application:

Title of Invention/Application: Interferon Beta-Like Molecules for Treatment of Stroke

Filing Date: 28 February 2003

Application No.: PCT/DK03/00127 ; and.

**COPY**

WHEREAS, Maxygen ApS, a company existing under the laws of Denmark, located at Agern Allé 1, DK-2970 Hørsholm, Denmark, is an owner and co-applicant of the above-identified international patent application PCT Appn. No. PCT/DK03/00127, hereinafter referred to as "Assignee," is desirous of acquiring all interest in the invention, application, and in any Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by these presents does assign to Assignee all right, title and interest in and to the invention and application and to all national phase and foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in all countries throughout the world, and which claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignor further agrees that Assignor will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of the above-identified international patent application and any national phase and foreign counterparts on the application and invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the application and invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNOR has signed his/her name on the date indicated.

Date: 26 July 2004  
Place: Valby

SIGNATURE WITNESSED BY:

Date: 26 July 2004  
Place: Valby

Lars Bokjerumgaard  
Assignor H. Lundbeck (please sign and print/title of representative)  
LARS BOKJERRUMGAARD, SECTION LEADER,  
CORPORATE PATENTS

Vibeke Møller Nielsen  
Signature of Witness

VIBEKE MØLLER NIELSEN  
Printed Name of Witness

ASSIGNEE:

Date: 27 July 2004  
Place: Hørsholm, DK

SIGNATURE WITNESSED BY:

Date: 27 July 2004  
Place: Hørsholm, DK

Jeffrey Salka  
Assignee Maxygen ApS (please sign and print name/title of representative)  
Jeffrey Salka, Senior Patent Counsel

Kirsten Høgh  
Signature of Witness

KIRSTEN HØGH  
Printed Name of Witness